SCHEMBL1404043

SCHEMBL1404043

CCCN(CC)CCCCO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TSHR P16473 1/20 0.43
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
HIF1A Q16665 1/20 0.39
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KCNH2 Q12809 5/20 0.37
CHRM2 P08172 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
CHRM1 P11229 1/20 0.34
DRD1 P21728 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27956502 0.98 LMNA (0.48) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL1404003 0.92 ALDH1A1 (0.43) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL465376 0.92 SMN1; SMN2 (0.45) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL1404078 0.90 SMN1; SMN2 (0.52) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL465469 0.90 ALDH1A1 (0.48) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL465358 0.90 ALDH1A1 (0.48) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL5052250 0.90 SMN1; SMN2 (0.43) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL465374 0.90 SMN1; SMN2 (0.50) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL975581 0.90 SMN1; SMN2 (0.50) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL25504769 0.89 LMNA (0.52) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399409-B1 METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS BASF SE (DE) 2012-10-31 EP claimed
CN-100349854-C Method for producing (meth) acrylic acid esters BASF AG (DE) 2007-11-21 CN claimed
US-7268251-B2 Method for producing (meth) acrylic acid esters BASF AKTIENGESELLSCHAFT (DE) 2007-09-11 US claimed
US-7026503-B2 Method for producing (meth)acrylic acid esters BASF AKTIENGESELLSCHAFT (DE) 2006-04-11 US claimed
EP-1399408-B1 METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS BASF AG (DE) 2006-03-22 EP claimed
US-10174349-B2 Recombinant cell producing 2-hydroxyisobutyric acid EVONIK ROEHM GMBH (DE) 2019-01-08 US disclosed
EP-2291530-B1 RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID EVONIK ROEHM GMBH (DE) 2018-12-26 EP disclosed
CN-107083352-A Produce the recombinant cell of 2 hydroxy-iso-butyric acids 赢创罗姆有限公司 2017-08-22 CN disclosed
WO-2017032699-A1 METHOD FOR PRODUCING LOW-BOILING (METH)ACRYLIC ACID ESTERS BASF SE (DE) 2017-03-02 WO disclosed
EP-2125771-B1 PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE EVONIK ROEHM GMBH (DE) 2013-03-20 EP disclosed
US-8207371-B2 Process for preparing (meth)acrylic acid EVONIK RÖHM GMBH (DE) 2012-06-26 US disclosed
US-20110171702-A1 RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID EVONIK ROEHM GMBH (DE) 2011-07-14 US disclosed
EP-2291530-A1 RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID Evonik Röhm GmbH (DE) 2011-03-09 EP disclosed
US-20100029979-A1 PROCESS FOR PREPARING (METH)ACRYLIC ACID EVONIK ROEHM GMBH (DE) 2010-02-04 US disclosed
US-20100010276-A1 PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE EVONIK ROEHM GMBH (DE) 2010-01-14 US disclosed
WO-2009156214-A1 RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID EVONIK RÖHM GMBH (DE) 2009-12-30 WO disclosed
EP-2125771-A1 PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE Evonik Röhm GmbH (DE) 2009-12-02 EP disclosed
EP-2091906-A1 PROCESS FOR PREPARING (METH)ACRYLIC ACID Evonik Röhm GmbH (DE) 2009-08-26 EP disclosed
WO-2008061819-A1 PROCESS FOR PREPARING (METH)ACRYLIC ACID EVONIK RÖHM GMBH (DE) 2008-05-29 WO disclosed
WO-2008061821-A1 PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE EVONIK RÖHM GMBH (DE) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029979-A1 PROCESS FOR PREPARING (METH)ACRYLIC ACID MMAB, ASS1, PAM SMN1; SMN2 3577/4885LMNA 3634/4885ALDH1A1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.